Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec;84(4):471-8.

Medical reversal: why we must raise the bar before adopting new technologies

Affiliations

Medical reversal: why we must raise the bar before adopting new technologies

Vinay Prasad et al. Yale J Biol Med. 2011 Dec.

Abstract

Medical reversal occurs when a new clinical trial - superior to predecessors by virtue of better controls, design, size, or endpoints - contradicts current clinical practice. In recent years, we have witnessed several instances of medical reversal. Famous examples include the class 1C anti-arrhythmics post-myocardial infarction (contradicted by the CAST trial) or routine stenting for stable coronary disease (contradicted by the COURAGE trial). In this paper, we explore the phenomenon of medical reversal. The causes and consequences are discussed. Conflicts of interest among researchers and an unyielding faith in basic science are explored as root causes of reversal. Reversal harms patients who undergo the contradicted therapy during the years it was in favor and those patients who undergo the therapy in the lag time before a change in medical practice. Most importantly, it creates a loss of faith in the medical system by physicians and patients. The solution to reversal is upfront, randomized clinical trials for new clinical practices and a systematic method to evaluate practices already in existence.

Keywords: basic science; contradicted findings; evidence-based medicine; medical reversal; observational studies; randomized controlled trials.

PubMed Disclaimer

References

    1. Lee AYY, Levine MS, Baker RI. et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153. - PubMed
    1. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther. 2001;23(7):998–1017. - PubMed
    1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471. - PubMed
    1. Taylor AJ, Villines TC, Stanek EJ. et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2007;361:2113–2122. - PubMed
    1. Carlberg B, Samuelsson O, Lindholm L. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684. - PubMed

MeSH terms